Sequential Analysis of cfDNA Reveals Clonal Evolution in Patients with Neuroblastoma Receiving ALK-Targeted Therapy.

doi:10.1158/1078-0432.CCR-24-0753

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Sequential Analysis of cfDNA Reveals Clonal Evolution in Patients with Neuroblastoma Receiving ALK-Targeted Therapy.

Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Aug 2024

Bobin Charles, Iddir Yasmine, Butterworth Charlotte, Masliah-Planchon Julien, Saint-Charles Alexandra, Bellini Angela, Bhalshankar Jaydutt, Pierron Gaelle, Combaret Valérie, Attignon Valéry, André Nicolas, Corradini Nadège, Dumont Benoit, Mansuy Ludovic, Khanfar Camille, Klein Sebastien, Briandet Claire, Plantaz Dominique, Millot Frederic, Thouvenin Sandrine, Aerts Isabelle, Ndounga-Diakou Lee Aymar, Laghouati Salim, Abbou Samuel, Jehanno Nina, Tissot Hubert, Renault Shufang, Baulande Sylvain, Raynal Virginie, Bozec Laurence, Bieche Ivan, Delattre Olivier, Berlanga Pablo, Schleiermacher Gudrun

Abstract excerpt

PURPOSE: The study of cell-free DNA (cfDNA) enables sequential analysis of tumor cell-specific genetic alterations in patients with neuroblastoma. EXPERIMENTAL DESIGN: Eighteen patients with relapsing neuroblastoma having received lorlatinib, a third-generation ALK inhibitor, were identified (SACHA national registry and/or in the institution). cfDNA was analyzed at relapse for nine patients and sequentially for...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Aminopyridines

Share to Anaplastic Lymphoma Kinase

Share to Cell-Free Nucleic Acids

Share to Clonal Evolution

Share to Lactams

Share to Neoplasm Recurrence, Local

Share to Neuroblastoma

Share to Pyrazoles

Source

Open in PubMed Open full text

Identifiers

PMID: 38787533
DOI: 10.1158/1078-0432.CCR-24-0753
PMCID: PMC11292203

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Sequential Analysis of cfDNA Reveals Clonal Evolution in Patients with Neuroblastoma Receiving ALK-Targeted Therapy.PMID 38787533Read ↗

Whole-Exome Sequencing of Cell-Free DNA Reveals Temporo-spatial Heterogeneity and Identifies Treatment-Resistant Clones in Neuroblastoma.Semantic proximity Read ↗

Long-Lasting Response to Lorlatinib in Patients with ALK-Driven Relapsed or Refractory Neuroblastoma Monitored with Circulating Tumor DNA Analysis.Semantic proximity Read ↗

Circulating tumor DNA reveals mechanisms of lorlatinib resistance in patients with relapsed/refractory ALK-driven neuroblastoma.Semantic proximity Read ↗

A Quantitative Analysis of Subclonal and Clonal Gene Mutations before and after Therapy in Chronic Lymphocytic Leukemia.Semantic proximity Read ↗

Longitudinal Whole-Exome Sequencing of Cell-Free DNA Reveals Molecular Evolution and Heterogeneous Clinical Outcomes in PD-L1 Stratified Advanced NSCLC Adenocarcinoma Patients Treated with Atezolizumab.Semantic proximity Read ↗

Serial Profiling of Circulating Tumor DNA Identifies Dynamic Evolution of Clinically Actionable Genomic Alterations in High-Risk Neuroblastoma.Semantic proximity Read ↗

Frequency and Clinical Significance of Clonal and Subclonal Driver Mutations in High-Risk Neuroblastoma at Diagnosis: A Children's Oncology Group Study.Semantic proximity Read ↗

Targeted Analysis of Cell-free Circulating Tumor DNA is Suitable for Early Relapse and Actionable Target Detection in Patients with Neuroblastoma.Semantic proximity Read ↗

Longitudinal monitoring by next-generation sequencing of plasma cell-free DNA in ALK rearranged NSCLC patients treated with ALK tyrosine kinase inhibitors.Semantic proximity Read ↗

Neuroblastoma Molecular Risk-Stratification of DNA Copy Number and ALK Genotyping via Cell-Free Circulating Tumor DNA ProfilingSemantic proximity Read ↗

Serial Next-Generation Sequencing of Circulating Cell-Free DNA Evaluating Tumor Clone Response To Molecularly Targeted Drug Administration.Semantic proximity Read ↗

Plasma cfDNA analysis of alectinib resistance-related gene alterations in the J-ALEX studySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.